Literature DB >> 15883284

Effect of intravitreal triamcinolone acetonide on susceptibility to experimental bacterial endophthalmitis and subsequent response to treatment.

Rodney S Bucher1, Edward Hall, David M Reed, Julia E Richards, Mark W Johnson, David N Zacks.   

Abstract

OBJECTIVES: Recent reports of high endophthalmitis rates after intravitreal triamcinolone acetonide injection have raised concerns about the safety of this treatment. We sought to evaluate the effect of intravitreal triamcinolone injection on (1) the susceptibility to experimental bacterial endophthalmitis and (2) the subsequent therapeutic response to antibiotic treatment.
DESIGN: For the susceptibility study, the right eye of 40 New Zealand white rabbits received an intravitreal injection of a known quantity of Staphylococcus epidermidis organisms. Half of the eyes received a simultaneous intravitreal injection of triamcinolone acetonide, 4 mg. All eyes were examined daily for signs of endophthalmitis (photophobia, conjunctival injection, and vitritis) using standardized grading protocols (scaled from 0 to 4 with increasing severity). On day 7, vitreous cultures were obtained. For the therapeutic response study, the right eye of 12 rabbits received an intravitreal injection of S epidermidis organisms sensitive to vancomycin. Half of the eyes received a simultaneous intravitreal injection of triamcinolone acetonide, 4 mg. All 12 eyes received an intravitreal injection of vancomycin hydrochloride, 1 mg, on development of the first signs of endophthalmitis. All eyes were examined daily for 7 additional days. On day 7 after treatment, vitreous cultures were obtained.
RESULTS: In the susceptibility study, all 40 eyes developed signs of endophthalmitis. In eyes that received intravitreal bacteria plus triamcinolone, 17 (85%) of the 20 vitreous cultures were positive, whereas only 6 (30%) were positive in the 20 eyes receiving bacteria alone (P = .001). The vitritis was significantly increased in the bacteria plus triamcinolone group compared with the bacteria-only group (17 of 20 vs 7 of 20 with 4+ vitritis, respectively; P = .003). In the therapeutic response study, all 12 eyes developed clinical signs of endophthalmitis within 48 hours. All vitreous samples obtained 7 days after intravitreal vancomycin injection were culture negative. However, the severity of vitritis at the time of vitreous sampling was less in the eyes receiving triamcinolone plus bacteria compared with eyes receiving bacteria alone (0 of 6 vs 5 of 6 with 4+ vitritis, respectively; P = .02).
CONCLUSIONS: In eyes with experimentally induced bacterial endophthalmitis, the presence of intravitreal triamcinolone results in a higher culture-positive rate and a higher degree of inflammation, suggesting an impaired ocular immune response and greater susceptibility to infection. However, in eyes with experimentally induced bacterial endophthalmitis receiving early treatment with intravitreal antibiotics, triamcinolone appears to suppress the ocular inflammatory response without impairing the therapeutic effect. CLINICAL RELEVANCE: These data suggest that caution must be exercised when combining intravitreal triamcinolone injection with intraocular surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15883284     DOI: 10.1001/archopht.123.5.649

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  11 in total

Review 1.  Infectious crystalline keratopathy associated with intravitreal and posterior sub-Tenon triamcinolone acetonide injections.

Authors:  D A Hollander; E L Clay; Y Sidikaro
Journal:  Br J Ophthalmol       Date:  2006-05       Impact factor: 4.638

Review 2.  A Review of the Role of Intravitreal Corticosteroids as an Adjuvant to Antibiotics in Infectious Endophthalmitis.

Authors:  Dawn Ching Wen Ho; Aniruddha Agarwal; Cecilia S Lee; Jay Chhablani; Vishali Gupta; Manoj Khatri; Jayabalan Nirmal; Carlos Pavesio; Rupesh Agrawal
Journal:  Ocul Immunol Inflamm       Date:  2016-11-16       Impact factor: 3.070

Review 3.  Evidence for and against intravitreous corticosteroids in addition to intravitreous antibiotics for acute endophthalmitis.

Authors:  Diem K Bui; Petros E Carvounis
Journal:  Int Ophthalmol Clin       Date:  2014

Review 4.  Modeling intraocular bacterial infections.

Authors:  Roger A Astley; Phillip S Coburn; Salai Madhumathi Parkunan; Michelle C Callegan
Journal:  Prog Retin Eye Res       Date:  2016-05-03       Impact factor: 21.198

Review 5.  Bacterial endophthalmitis in the age of outpatient intravitreal therapies and cataract surgeries: host-microbe interactions in intraocular infection.

Authors:  Ama Sadaka; Marlene L Durand; Michael S Gilmore
Journal:  Prog Retin Eye Res       Date:  2012-04-11       Impact factor: 21.198

6.  The Association between Intravitreal Steroids and Post-Injection Endophthalmitis Rates.

Authors:  Brian L VanderBeek; Sarah G Bonaffini; Liyuan Ma
Journal:  Ophthalmology       Date:  2015-08-15       Impact factor: 12.079

7.  Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.

Authors:  Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler
Journal:  Clin Ophthalmol       Date:  2009-06-02

8.  Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.

Authors:  Florian Baudin; Eric Benzenine; Anne-Sophie Mariet; Alain M Bron; Vincent Daien; Jean François Korobelnik; Catherine Quantin; Catherine Creuzot-Garcher
Journal:  JAMA Ophthalmol       Date:  2018-12-01       Impact factor: 7.389

9.  Comparison of the short-term effects of intravitreal triamcinolone acetonide and bevacizumab injection for diabetic macular edema.

Authors:  Ju Hwan Song; Jung Joo Lee; Sang Joon Lee
Journal:  Korean J Ophthalmol       Date:  2011-05-24

10.  Intravitreal injections of anti-VEGF agents and antibiotic prophylaxis for endophthalmitis: A systematic review and meta-analysis.

Authors:  Manuel F Bande; Raquel Mansilla; María P Pata; Maribel Fernández; María José Blanco-Teijeiro; Antonio Piñeiro; Francisco Gómez-Ulla
Journal:  Sci Rep       Date:  2017-12-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.